CADTH Optimal Use Reports

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

A new version of this title is available

This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

CADTH Optimal Use Reports

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2011-2021.

ISSN: 2563-6596

CADTH Optimal Use reports, now renamed to Health Technology Review, are intended to encourage ideal prescribing, purchasing, and use of drugs or other health technologies by health care providers, policy-makers, and consumers. Generally, these are drugs or health technologies that have been available in the marketplace for some time. An Optimal Use project results in a series of documents — typically clinical and economic review reports as well as a recommendations report. CADTH Optimal Use projects are carried out in collaboration with a committee or panel comprising subject‐matter experts, public representatives, and other stakeholders from across Canada.

The Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent, not-for-profit producer and broker of health technology assessments. Health care decision-makers rely on our work to make evidence-informed policy and practice decisions about drugs and other health technologies.

CADTH Optimal Use Reports was renamed to Health Technology Review on on Oct. 29, 2021, with volume 9.3c.

2020

Internet-Delivered Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder: Recommendations
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; January 2020.

2019

Axicabtagene Ciloleucel for Diffuse Large B-Cell Lymphoma: Economic Review Report
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2019.
Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Clinical Report
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2019.
Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Ethics and Implementation Report
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2019.
Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Health Technology Assessment Introduction and Clinical Review Protocol
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; May 2019.
Axicabtagene Ciloleucel for Large B-cell Lymphoma: Implementation and Ethics Project Protocol
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; May 2019.
Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Recommendations
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2019.
Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration
George A. Wells, Jesse Elliott, Shannon Kelly, Zemin Bai, Michel Boucher, Becky Skidmore, Derek So, Suzanne Laplante, and Karen Lee.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2019.
Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration — Recommendations
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2019.
HPV Testing for Primary Cervical Cancer Screening: A Health Technology Assessment
Clinical Review authors: Dr. Yi-Sheng Chao, Michelle Clark, Elizabeth Carson, Dr. Laura Weeks, Kristen Moulton, Dr. Susan McFaul, and Dr. C.M McLauchlin. Economic Evaluation author: Dr. Bernice Tsoi; Patients’ Perspectives and Experiences Review authors: Umair Majid, Sujane Kandasamy, Neha Arora, and Dr. Meredith Vanstone. Ethical Issues Analysis authors: Dr. Lynette Reid and Timothy Krahn. Implementation Issues Analysis author: Kasia Kaluzny; Research Information Specialist authors: Kelly Farrah and Caitlyn Ford.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2019.
HPV Testing for Primary Cervical Cancer Screening: Recommendations Report
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2019.
Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: Patients’ Perspectives and Experiences, Implementation, and Ethical Issues
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; February 2019.
Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: Recommendations
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2019.
Internet-Delivered Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder: A Health Technology Assessment
Clinical review authors: Calvin Young and Dr. Alison Sinclair. Economic evaluation authors: Cody Black; Perspectives and experiences review authors: Elijah Herington; Implementation issues analysis author: Elijah Herington; Ethics analysis author: Dr. Maxwell Smith; Research information specialist authors: Carolyn Spry and Kaitryn Campbell. Program development officer: Bert Dolcine.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; December 2019.
Internet-Delivered Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder: A Health Technology Assessment — Project Protocol
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; July 2019.
Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment
Clinical Review Authors: Dr. Veronica Poitras, Charlotte Wells, and Dr. Cindy Hutnik. Economic Evaluation Authors: Dr. Scott Klarenback, Helen So, and Dr. Bernice Tsoi. Patients’ Perspectives and Experiences Review Authors: Andrea Smith and Elijah Herington. Ethical Issues Analysis Author: Natalie Brender; Implementation Issues Analysis author: Charlotte Wells; Research Information Specialist authors: Caitlyn Ford and Melissa Severn.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; January 2019.
Optimal Use of Minimally Invasive Glaucoma Surgery: Recommendations
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2019.

2018

Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration — Project Protocol
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; February 2018.
Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment — Project Protocol
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; June 2018.
Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment
Clinical Authors: Alison Sinclair, Kwakye Peprah, Teo Quay, Matthew McInnis, Eddy Lang, Melissa Severn, Sohail Mulla, and Laura Weeks. Bernice Tsoi, Economic Author; Patient Perspectives and Experiences Authors: Elijah Herrington and Myuri Manogaran. Sarah Garland, Implementation Author; Angel Petropaganos, Ethics Author; Environmental Authors: Kwakye Peprah and Julie Polisena.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; January 2018.
Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: Recommendations
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2018.
Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment — Project Protocol
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; January 2018.
Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Clinical Section
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2018.
Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Implementation and Ethics Section
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; September 2018.

2017

Current Practice Analysis: Interventions for Insomnia Disorder
Janet Crain, Michael Raj, Sarah Garland, Sarah Jones, and Bechara Farah.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; June 2017.
Dialysis Modalities for the Treatment of End-Stage Kidney Disease: A Health Technology Assessment
Clinical authors: Dr. Alison Sinclair, Karen Cimon, Mirhad Loncar, Dr. Manish Sood, Dr. Paul Komenda, and Melissa Severn. Economic authors: Dr. Scott Klarenbach, Dr. Helen So, Dr. Bernice Tsoi, Dr. Robert Quinn, Dr. Robert Pauly, Dr. Marcello Tonelli, and Dr. Braden Manns. Patient preferences and experiences authors: Tamara Rader and Kristen Moulton. Implementation authors: Kristen Moulton, Eftyhia Helis, and Janet Crain. Ethics author: Dr. Daryl Pullman.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2017.
Dialysis Modalities for the Treatment of End-Stage Kidney Disease: Recommendations
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2017.
HPV Testing for Primary Cervical Cancer Screening — Project Protocol
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; May 2017.
Interventions for the Treatment of Obstructive Sleep Apnea in Adults: A Health Technology Assessment
Joanne Kim, Khai Tran, Kelsey Seal, Almeida Fernanda, Ross Glenda, Roch Messier, Major, Bernice Tsoi, Sarah Garland, Tamara Rader, Katherine Duthie, Ken Bond, Janice Mann, Kelsey Seal, and David Kaunelis.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2017.
Interventions for the Treatment of Obstructive Sleep Apnea in Adults: Recommendations
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2017.

2016

Addendum to Interventions for the Treatment of Obstructive Sleep Apnea in Adults: A Health Technology Assessment – Project Protocol
Khai Tran, Joanne Kim, Bernice Tsoi, Tamara Rader, Sarah Garland, Katherine Duthie, Ken Bond, Kelsey Seal, David Kaunelis, Dr. Fernanda Almeida, Lt. Col. Glenda Ross, and Major Roch Messier.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; June 2016.
Dialysis Modalities for the Treatment of End-Stage Kidney Disease: A Health Technology Assessment — Project Protocol
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; November 3, 2016.
DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: A Health Technology Assessment
Clinical authors: Nazila Assasi, Gordon Blackhouse, Kaitryn Campbell, Katherine Gaebel, Robert Hopkins, Jathishinie Jegathisawaran, Alison Sinclair, Kelsey Seal, Chris Kamel, and Mitchell Levine. Economic authors: Gordon Blackhouse, Bernice Tsoi, Kaitryn Campbell, and Jathishinie Jegathisawaran. Patient Preferences and Experiences authors: Laura Weeks, Sarah Garland, Kristen Moulton, and David Kaunelis.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2016.
DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: Ethical Issues
Katherine Duthie, Ken Bond, and David Kaunelis.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2016.
DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: Recommendations
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2016.
Interventions for the Treatment of Obstructive Sleep Apnea in Adults: A Health Technology Assessment – Project Protocol
Khai Tran, Joanne Kim, Bernice Tsoi, Tamara Rader, Sarah Garland, Katherine Duthie, Ken Bond, Kelsey Seal, Dr. Fernanda Almeida, Lt. Col. Glenda Ross, and Major Roch Messier.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; April 2016.
Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients: A Clinical and Cost-Effectiveness Analysis and Review of Patient Preferences
Gino De Angelis, Karen Cimon, Alison Sinclair, Kelly Farrah, Dr John Cairns, and Dr Adrian Baranchuk. Lauren E Cipriano and A Omar Akhtar. Laura Weeks, Tamara Rader, and Sarah Garland.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2016.
Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients: Recommendations
Gino De Angelis, Karen Cimon, Alison Sinclair, Kelly Farrah, Dr. John Cairns, and Dr. Adrian Baranchuk. Lauren E. Cipriano and A. Omar Akhtar. Laura Weeks, Tamara Rader, and Sarah Garland.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2016.
Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment — Project Protocol
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; September 29, 2016.
Point-of-Care Troponin Testing in Patients With Symptoms Suggestive of Acute Coronary Syndrome: A Health Technology Assessment
Chuong Ho, Karen Cimon, Laura Weeks, Monika Mierzwinski-Urban, and Lesley Dunfield. Lesley Soril, Fiona Clement, and Mohammed Jabr.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2016.
Point-of-Care Troponin Testing in Patients With Symptoms Suggestive of Acute Coronary Syndrome: Recommendations
Chuong Ho, Karen Cimon, Laura Weeks, Monika Mierzwinski-Urban, and Lesley Dunfield. Lesley Soril, Fiona Clement, and Mohammed Jabr.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2016.

2015

Effectiveness of Factor V Leiden and Prothrombin Mutation Testing in Patients Presenting With a First Unprovoked Venous Thromboembolic Episode: A Systematic Review and Economic Analysis
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2015.
Guidance on the Use of Factor V Leiden and Prothrombin Mutation Testing in Patients With a First Unprovoked Thromboembolic Episode
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2015.
Mismatch Repair Deficiency Testing for Patients with Colorectal Cancer: A Clinical and Cost-Effectiveness Evaluation
Nazila Assasi, Gord Blackhouse, Kaitryn Campbell, Laura Weeks, and Mitchell Levine.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; September 2015.
Monitoring for Atrial Fibrillation in Discharged Stroke and Transient Ischemic Attack Patients: A Clinical and Cost-Effectiveness Analysis and Review of Patient Preferences
Gino De Angelis, Karen Cimon, Lauren Cipriano, Kelly Farrah, Sarah Garland, Dr John Cairns, and Dr Adrian Baranchuk.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; September 2015.
Point-of-Care Cardiac Troponin Testing in Patients With Symptoms Suggestive of Acute Coronary Syndrome – Project Protocol
Chuong Ho, (Research Officer/Project Lead/Co-Author), Karen Cimon, (Research Assistant/Co-Author), Mohammed Jabr, (Health Economist/Co-Author), Monika Mierzwinski-Urban, (Information Specialist/Co-Author), Fiona Clement, (Health Economist/Co-Author), Lesley Soril, (Research Analyst/Co-Author), Lesley Dunfield, (Director, HTA), Laura Weeks, (Scientific Advisor), and Pat Reynard, (Project Manager).
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; June 2015.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK168999PMID: 37643250

PubReader
Print View
Cite this Page
CADTH Optimal Use Reports. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2011-2021.

Recent Activity

Clear Turn Off Turn On

CADTH Optimal Use Reports
CADTH Optimal Use Reports
High-Sensitivity Cardiac Troponin for the Rapid Diagnosis of Acute Coronary Synd...
High-Sensitivity Cardiac Troponin for the Rapid Diagnosis of Acute Coronary Syndrome in the Emergency Department: A Clinical and Cost-Effectiveness Evaluation

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

CADTH Optimal Use Reports

Contents

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

Views

Similar articles in PubMed

Recent Activity